Cell therapy
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post-Launch
Mesoblast (MESO) reported Q1 FY2026 results with cell therapy revenue of $20.6M, up from $12.9M sequentially. Ryoncil gross sales rose 66% to $21.9M; net sales increased 69% to $19.1M after adjustments. A permanent Ryoncil J-code (J3402) became active 10/1/25 and federal Medicaid coverage is mandatory from 7/1/25. The company held $145M cash and secured convertible note agreements for up to $50M (subject to approval). They onboarded 40 transplant centers with coverage over 260M lives.
